NPACT- Naturally occuring Plant based Anticancerous Compound-Activity-Target DataBase

Compound: Fisetin

TargetsGene NameGene IDCancerCell LinesIC50ED50EC50GI50RemarkReferences
BAK1BCL2-antagonist/killer 1578Colon CancerHT-29----The treatment of cells with Fisetin increased level of proapoptotic Bak protein.19037088
BCL2B-cell CLL/lymphoma 2596Colon CancerHT-29----The treatment of cells with Fisetin decreased the level of prosurvival Bcl-2.19037088
BCL2L1BCL2-like 1598Colon CancerHT-29----The treatment of cells with Fisetin decreased the level of Bcl-XL proteins.19037088
CCND1cyclin D1595Colon CancerHT-29----The cyclin D1 levels were also lower at 4, 8, and 12 h in cells treated with 60 µmol/L .16317137
CCNE1cyclin E1898Colon CancerHT-29----Cyclin E was decreased in HT-29 cells within 2 h after treatment with 60µmol/L Fisetin. At 8 h, cyclin E was decreased in cells treated with 40µmol/L Fisetin.16317137
CDC25Ccell division cycle 25 homolog C (S. pombe)995Colon CancerHT-29----The protein levels of CDC2 and CDC25C decreased in cells treated with 40 mol/L Fisetin, whereas that of p-CDC2 (Tyr15) increased in cells treated with 20 mol/L Fisetin (P<0.05.16317137
CDK1cyclin-dependent kinase 1983Colon CancerHT-29----The activity of CDC2 were also decreased in fisetin-treated cells (P < 0.05).16317137
CDK2cyclin-dependent kinase 21017Colon CancerHT-29----Fisetin decreased the activities of cyclin-dependent kinases CDK.16317137
CDK4cyclin-dependent kinase 41019Colon CancerHT-29----CDK4 activity was drastically decreased within 30 min of Fisetin treatment, which was consistently lower in Fisetin-treated cells throughout the 12-h incubation period (P< 0.05).Fisetin also inhibited CDk4 activity in a cell-free system (P < 0.05), indicating that it may directly inhibit CDk4 activity.16317137
CDKN1Acyclin-dependent kinase inhibitor 1A (p21, Cip1)1026Colon CancerHT-29----Fisetin increased the p21 levels at 8 and 12 h and the increased p21 at 8 h was dependent on the dose of Fisetin.16317137
COX-2cytochrome c oxidase subunit II4513Colon CancerHT-29----Treatment of the cells with 60 microM of Fisetin significantly diminished COX2 protein expression and almost abolished the COX2 expression at a dose of 120 lM of Fisetin.19037088
EGFRepidermal growth factor receptor1956Colon CancerHT-29----HT29 cells treated with Fisetin exhibited decreased EGFR phosphorylation as low as at 30 microM.19037088
NFKB1nuclear factor of kappa light polypeptide gene enhancer in B-cells 14790Colon CancerHT-29----Fisetin treatment (30, 60, 90, 120 microM) resulted in decrease of NF-kappaB transcriptional activity by 3.7, 41.0, 62.3 and 78.6%, respectively.19037088
PTGER3prostaglandin E receptor 3 (subtype EP3)5733Colon CancerHT-29----Inhibition of PGE2 release by Fisetin occurred dose dependently.When cells were treated with 60 and 120 lM of Fisetin, the secretion of PGE2 was decreased by 32.6 and 82.0%,respectively.19037088
RB1retinoblastoma 15925Colon CancerHT-29----The phosphorylation state of the retinoblastoma proteins shifted from hyperphosphorylated to hypophosphorylated in cells treated with 40 micromol/L fisetin. (P < 0.05.16317137

 






Copyright © 2012. Subhash M. Agagrwal. All Rights Reserved.